TUKYSA in Combination with Antibody-Drug Conjugate ado-Trastuzumab Emtansine Improves Progression-Free Survival in Patients with Previously Treated HER2-Positive Metastatic Breast Cancer
| FRBRX Fund | USD 141.38 6.06 4.11% |
Slightly above 61% of Franklin Biotechnology's investor base is looking to short. The analysis of overall sentiment of trading Franklin Biotechnology Discovery mutual fund suggests that many investors are alarmed at this time. Franklin Biotechnology's investing sentiment can be driven by a variety of factors including economic data, Franklin Biotechnology's earnings reports, geopolitical events, and overall market trends.
Franklin |
Seagen Inc. today announced data from the Phase 3 HER2CLIMB-02 clinical trial of TUKYSA in combination with the antibody-d
Read at businesswire.com
 |
Franklin Biotechnology Fundamental Analysis
We analyze Franklin Biotechnology's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Franklin Biotechnology using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Franklin Biotechnology based on its fundamental data. In general, a quantitative approach, as applied to this mutual fund, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Five Year Return
Five Year Return Comparative Analysis
Franklin Biotechnology is currently under evaluation in five year return among similar funds. Five Year Return is considered one of the best measures to evaluate fund performance, especially from the mid and long term perspective. It shows the total annualized return generated from holding equity for the last five years and represents capital appreciation of the investment, including all dividends, losses, and capital gains distributions.
Franklin Biotechnology Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Franklin Biotechnology mutual fund to make a market-neutral strategy. Peer analysis of Franklin Biotechnology could also be used in its relative valuation, which is a method of valuing Franklin Biotechnology by comparing valuation metrics with similar companies.
Peers
Franklin Biotechnology Related Equities
| TEGBX | Templeton Global | 0.59 |
| ||
| TEDSX | Franklin Mutual | 0.67 |
| ||
| TEFTX | Templeton Foreign | 0.75 |
| ||
| TEDMX | Templeton Developing | 1.68 |
| ||
| TEDRX | Franklin Mutual | 2.17 |
| ||
| TEDIX | Franklin Mutual | 2.19 |
| ||
| TEGRX | Templeton Growth | 2.50 |
| ||
| TEBIX | Franklin Mutual | 2.60 |
| ||
| TEMFX | Templeton Foreign | 2.63 |
| ||
| TEFRX | Templeton Foreign | 2.70 |
|
Other Information on Investing in Franklin Mutual Fund
Franklin Biotechnology financial ratios help investors to determine whether Franklin Mutual Fund is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Franklin with respect to the benefits of owning Franklin Biotechnology security.
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device |